Baxter International Inc.
BAX · New York Stock Exchange · USD
26,41USD
+0,62 (+2,40 %)Stand 9. Nov., 21:00
Nachbörslich26,20−0,21 (−0,80 %)17:48 ET
Kennzahlen
- Eröffnung
- 26,17
- Vortag
- 25,79
- Tagesspanne
- 25,87 – 26,71
- 52 Wochen
- 15,73 – 30,00
- Volumen
- 4,54 Mio.
- Ø Volumen
- 6,76 Mio.
- Börsenwert
- 13,66 Mrd. $
- KGV
- -19,1
- Gewinn je Aktie (TTM)
- -1,38
- Dividendenrendite
- 0,2 %
- Beta
- 0,7
- Nächste Zahlen
- 11. Feb. 2027
Finanzen
| USD | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Umsatz | 11,24 Mrd. | 10,64 Mrd. | 10,36 Mrd. | 10,06 Mrd. | 12,15 Mrd. |
| Herstellungskosten | 7,87 Mrd. | 6,65 Mrd. | 6,21 Mrd. | 6,51 Mrd. | 7,43 Mrd. |
| Bruttogewinn | 3,38 Mrd. | 3,98 Mrd. | 4,15 Mrd. | 3,55 Mrd. | 4,72 Mrd. |
| Forschung und Entwicklung | 518 Mio. | 590 Mio. | 518 Mio. | 450 Mio. | 531 Mio. |
| Vertrieb und Verwaltung | 2,89 Mrd. | 2,97 Mrd. | 2,95 Mrd. | 3,1 Mrd. | 2,85 Mrd. |
| Operatives Ergebnis | −308 Mio. | 14 Mio. | 707 Mio. | −2,85 Mrd. | 1,35 Mrd. |
| EBITDA | 766 Mio. | 1,12 Mrd. | 1,73 Mrd. | −1,76 Mrd. | 2,19 Mrd. |
| Nettogewinn | −957 Mio. | −649 Mio. | 2,66 Mrd. | −2,43 Mrd. | 1,28 Mrd. |
| Gewinn je Aktie (verwässert) | -1,75 | -1,27 | 5,23 | -4,83 | 2,53 |
Umsatz nach Segment
Produkte · FY 2025
- Medical Products And Therapies5,3 Mrd. $48,78 %+1,77 %
- Healthcare Systems and Technologies3,07 Mrd. $28,27 %+4,07 %
- Pharmaceuticals2,49 Mrd. $22,95 %+3,40 %
Anteil · ggü. Vorjahr (FY 2024)
Regionen · FY 2025
- UNITED STATES6,12 Mrd. $54,45 %+4,65 %
- Western Europe, Canada, Japan, Australia and New Zealand3,73 Mrd. $33,16 %+8,50 %
- EMEA1,39 Mrd. $12,40 %+3,26 %
Anteil · ggü. Vorjahr (FY 2024)
Bewertung
Letzte 12 Monate
- KGV
- -19,1
- Kurs-Umsatz-Verhältnis
- 1,2
- Kurs-Buchwert-Verhältnis
- 2,1
- PEG
- 0,1
- Bruttomarge
- 30,1 %
- Operative Marge
- −1,9 %
- Nettomarge
- −6,2 %
- Verschuldungsgrad
- 1,4
- EV/EBITDA
- 25,6
- Eigenkapitalrendite
- −11,6 %
- Kapitalrendite (ROIC)
- −1,3 %
- Free-Cashflow-Rendite
- 7,3 %
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Bruttomarge | 30,1 % | 37,5 % | 40,1 % | 35,3 % | 38,9 % |
| Operative Marge | −2,7 % | 0,1 % | 6,8 % | −28,3 % | 11,1 % |
| Nettomarge | −8,5 % | −6,1 % | 25,6 % | −24,2 % | 10,6 % |
| KGV | -10,9 | -23,0 | 7,4 | -10,6 | 33,5 |
| Kurs-Umsatz-Verhältnis | 0,9 | 1,4 | 1,9 | 2,6 | 3,5 |
| Kurs-Buchwert-Verhältnis | 1,6 | 2,1 | 2,3 | 4,4 | 4,7 |
| Verschuldungsgrad | 1,6 | 1,9 | 1,7 | 2,9 | 2,0 |
| Liquidität 3. Grades | 2,3 | 1,4 | 1,5 | 1,7 | 2,1 |
| Dividendenrendite | 3,5 % | 4,0 % | 3,0 % | 2,2 % | 1,2 % |
| Unternehmenswert | 17,84 Mrd. | 26,56 Mrd. | 30,6 Mrd. | 41,17 Mrd. | 58,45 Mrd. |
| EV/EBITDA | 23,3 | 23,8 | 17,6 | -23,4 | 26,7 |
| Eigenkapitalrendite | −15,6 % | −9,3 % | 31,6 % | −41,7 % | 14,1 % |
| Kapitalrendite (ROIC) | −1,8 % | 0,1 % | 2,2 % | −10,9 % | 4,2 % |
| Free-Cashflow-Rendite | 3,3 % | 3,8 % | 6,6 % | 2,2 % | 3,6 % |
Wachstum
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | |
|---|---|---|---|---|---|
| Umsatz | +5,7 % | +2,7 % | +3,0 % | −17,2 % | +4,1 % |
| Bruttogewinn | −15,2 % | −4,0 % | +16,9 % | −24,8 % | +2,9 % |
| Operatives Ergebnis | −2.300,0 % | −98,0 % | +124,9 % | −310,7 % | −16,5 % |
| Nettogewinn | −47,5 % | −124,4 % | +209,2 % | −289,5 % | +16,5 % |
| Gewinn je Aktie | −37,8 % | −124,3 % | +208,3 % | −290,9 % | +18,8 % |
| Freier Cashflow | −42,2 % | −56,7 % | +124,0 % | −62,4 % | +32,1 % |
| Dividende je Aktie | −41,4 % | −0,1 % | +1,9 % | +7,7 % | +13,6 % |
Analysten
Einstufungen · Hold
- 0Stark kaufen
- 14Kaufen
- 20Halten
- 2Verkaufen
- 0Stark verkaufen
Kursziel
23,83
Durchschnitt · −9,77 %
Schätzungen
| FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|
| Umsatz (Ø) | 11,72 Mrd. | 11,97 Mrd. | 12,24 Mrd. |
| Umsatz (Tief – Hoch) | 11,63 Mrd. – 11,77 Mrd. | 11,79 Mrd. – 12,06 Mrd. | 12,07 Mrd. – 12,58 Mrd. |
| Gewinn je Aktie (Ø) | 2,10 | 2,04 | 2,17 |
| Gewinn je Aktie (Tief – Hoch) | 2,05 – 2,12 | 1,75 – 2,13 | 1,38 – 3,42 |
| Analysten | 10 | 10 | 5 |
Letzte Änderungen
- Barclays9. Nov. 2026Underweight
- JP Morgan30. Okt. 2026Neutral
- Wells Fargo30. Okt. 2026Equal Weight
- Citigroup5. Okt. 2026Neutral
- Stifel31. Juli 2026Hold
- TD Cowen31. Juli 2026Hold
- Wells Fargo31. Juli 2026Equal Weight
- Citigroup31. Juli 2026Sell → Neutral
Quartalszahlen
Nächste Zahlen: 11. Feb. 2027| Okt. 2026 | Juli 2026 | Apr. 2026 | Feb. 2026 | Okt. 2025 | Juli 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,52 | 0,37 | 0,31 | 0,53 | 0,60 | 0,60 | 0,48 | 0,53 |
| Gewinn je Aktie · Tatsächlich | 0,58 | 0,56 | 0,36 | 0,44 | 0,69 | 0,59 | 0,55 | 0,58 |
| Abweichung | +11,97 % | +52,80 % | +15,76 % | −16,98 % | +15,00 % | −1,67 % | +13,75 % | +9,85 % |
| Umsatz · Tatsächlich | 2,98 Mrd. | 2,96 Mrd. | 2,7 Mrd. | 2,97 Mrd. | 2,84 Mrd. | 2,81 Mrd. | 2,63 Mrd. | 2,75 Mrd. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 27. Nov. 2026 | 4. Jan. 2027 | 0,01 |
| 28. Aug. 2026 | 1. Okt. 2026 | 0,01 |
| 29. Mai 2026 | 1. Juli 2026 | 0,01 |
| 27. Feb. 2026 | 1. Apr. 2026 | 0,01 |
| 28. Nov. 2025 | 2. Jan. 2026 | 0,01 |
| 29. Aug. 2025 | 1. Okt. 2025 | 0,17 |
| 30. Mai 2025 | 1. Juli 2025 | 0,17 |
| 28. Feb. 2025 | 1. Apr. 2025 | 0,17 |
| 29. Nov. 2024 | 2. Jan. 2025 | 0,17 |
| 30. Aug. 2024 | 1. Okt. 2024 | 0,29 |
| 31. Mai 2024 | 1. Juli 2024 | 0,29 |
| 29. Feb. 2024 | 1. Apr. 2024 | 0,29 |
Aktiensplits
- 1. Juli 20151841:1000
- 31. Mai 20012:1
- 1. Dez. 1992100000:90823
- 18. Nov. 19832:1
- 9. Nov. 19812:1
Eigentümer
Institutionen
Q2 2026 · 13F
- Anteil institutioneller Investoren
- 109,24 %
- Investoren mit 13F-Meldung
- 726
Größte Investoren
- BLACKROCK, INC.15,83 %81,84 Mio.
- PZENA INVESTMENT MANAGEMENT LLC12,63 %65,3 Mio.
- DODGE & COX11,29 %58,39 Mio.
- FMR LLC10,43 %53,91 Mio.
- VANGUARD CAPITAL MANAGEMENT LLC6,53 %33,75 Mio.
- VANGUARD PORTFOLIO MANAGEMENT LLC4,65 %24,06 Mio.
- STATE STREET CORP4,00 %20,6 Mio.
- GREENHAVEN ASSOCIATES INC2,76 %14,29 Mio.
Insider-Geschäfte
- Rogers Terence John1. Okt. 2026 · officer: EVP and CFOVerkauf0 Aktien
- Heine Bernard15. Sept. 2026 · officer: AVP, Finance InterimCAO&CntrlrVerkauf0 Aktien
- Hider Andrew P.2. Sept. 2026 · director, officer: President and CEOVerkauf54.276 Aktien · 25,70
- Foster Julie2. Sept. 2026 · officer: President, Front Line CareVerkauf2098 Aktien · 25,70
- Teaff James1. Sept. 2026 · officer: President, CCSVerkauf750 Aktien · 25,48
- Wilkes David S.5. Mai 2026 · directorKauf12.836 Aktien
- Wendell Amy McBride5. Mai 2026 · directorKauf12.836 Aktien
- SCHLICHTING NANCY M5. Mai 2026 · directorKauf12.836 Aktien
Vergleichbare Unternehmen
Über das Unternehmen
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devices vital for achieving hemostasis, tissue sealing, and preventing adhesions. Additionally, Baxter supplies continuous renal replacement therapies (CRRT) and other organ support solutions, primarily tailored for intensive care units. Beyond direct medical supplies, Baxter provides sophisticated connected care solutions, integrating devices, software, communication systems, and other advanced technologies. This includes a range of patient monitoring and diagnostic technologies designed to aid in the diagnosis, treatment, and management of numerous illnesses and conditions, spanning respiratory therapy, cardiology, vision screening, and physical assessment. The surgical suite benefits from its specialized video technologies, operating tables, lights, pendants, precision positioning tools, and various ancillary accessories. The company also offers contracted services to a multitude of pharmaceutical and biopharmaceutical companies. Baxter's products are utilized across diverse healthcare environments, including hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and for home-based patients under medical supervision. Operating in approximately 100 countries, Baxter distributes its extensive product line through a direct sales force, independent distributors, drug wholesalers, and specialty pharmacies or other alternative site providers. The company also holds a collaborative agreement with Celerity Pharmaceutical, LLC, focused on developing generic injectable pre-mixed medications for acute care and oncolytic molecules. Established in 1931, Baxter International Inc. is headquartered in Deerfield, Illinois.
Führung
- Andrew HiderChief Executive Officer, President, Interim Group President of Medical Products & Therapies and Director
- John Terence RogersExecutive Vice President & Chief Financial Officer
- Cynthia CarlisleExecutive Vice President & Chief Human Resources Officer
- David S. RosenbloomExecutive Vice President & General Counsel
- Maria SorianoGroup President of Infusion Therapies & Platforms
- Bernie HeineInterim Chief Accounting Officer & Controller
- CEO
- Andrew Hider
- Mitarbeitende
- 37.500
- Hauptsitz
- Deerfield, IL, US
- Sektor
- Healthcare
- Branche
- Medical - Instruments & Supplies
- Börsengang
- 27. Okt. 1981
- Website
- baxter.com
Nachrichten
- Defense World · 3. Nov., 3:53International Assets Investment Management LLC Acquires 72,405 Shares of Baxter International Inc. $BAX
- MarketBeat · 30. Okt., 3:14What Baxter International (BAX) Said on Its Q3 Earnings Call
- Zacks Investment Research · 29. Okt., 12:50Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook Raised
- Seeking Alpha · 29. Okt., 12:28Baxter International Inc. (BAX) Q3 2026 Earnings Call Transcript
- Benzinga · 29. Okt., 12:08Why Is Baxter Stock Trading Lower on Thursday?
- Zacks Investment Research · 29. Okt., 10:31Compared to Estimates, Baxter (BAX) Q3 Earnings: A Look at Key Metrics
- Zacks Investment Research · 29. Okt., 9:36Baxter International (BAX) Q3 Earnings and Revenues Surpass Estimates
- Business Wire · 29. Okt., 7:15Baxter Reports Third-Quarter 2026 Results
- Zacks Investment Research · 26. Okt., 12:26Will Baxter's Q3 Earnings Show Progress Despite Cost Pressures?
- Defense World · 16. Okt., 3:5820,728 Shares of Baxter International Inc. $BAX Acquired by Cohen Klingenstein LLC
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.